Prodrug based optimal drug delivery via membrane transporter/receptor

Expert Opinion on Biological Therapy

Volumn 1, Issue 2, 2001, Pages 159-175

  Yang, Chun ^a   Tirucherai, Giridhar S ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Active transport; Blood brain barrier; Carrier mediated transport; Drug targeting; Prodntg

Indexed keywords

AMINO ACID TRANSPORTER; BILE ACID BINDING PROTEINS; CARRIER PROTEIN; MONOCARBOXYLATE TRANSPORTER; MONOSACCHARIDE; PRODRUG;

ACTIVE TRANSPORT; ADSORPTION; ANIMAL; BLOOD BRAIN BARRIER; BRAIN; CELL MEMBRANE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG DESIGN; ENDOCYTOSIS; ENDOTHELIUM; EPITHELIUM; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW;

ADSORPTION; AMINO ACID TRANSPORT SYSTEMS; ANIMAL; BIOLOGICAL TRANSPORT, ACTIVE; BLOOD-BRAIN BARRIER; BRAIN; CARRIER PROTEINS; CELL MEMBRANE; DRUG DELIVERY SYSTEMS; DRUG DESIGN; ENDOCYTOSIS; ENDOTHELIUM; EPITHELIUM; HUMAN; MEMBRANE TRANSPORT PROTEINS; MONOCARBOXYLIC ACID TRANSPORTERS; MONOSACCHARIDES; PRODRUGS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0035289188     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.1.2.159     Document Type: Article

References (98)

1. NEUTRA M, KRAEHENBUHL JP: Transepithelial transport of proteins by intestinal epithelial cells. In: Biological Barriers to Protein Delivery. Audus KL, Raub TJ (Eds), Plenum Press, NY, USA (1993).
2. MURANISHI S, YAMAMOTO A, OKADA H: Rectal and vaginal absorption of peptides and proteins. In: Biological Barriers to Protein Delivery. Audus KL and Raub TJ (Eds), Plenum Press, NY, USA (1993):199-227.
3. HARRIS D, ROBINSON JR: Drug delivery via the mucous membrane of the oral cavity. J. Pbarm. Set. (1992) 81:1-10.
4. CHIEN YW, CHANG SF: Intranasal drug delivery for systemic medications. Crit. Rev. Tber. Drug Carrier Sys. (1987) 4:67-194.
5. JOHNSON LG, BOUCHER RC: Macromolecular transport across nasal and respiratory epithelia. In: Biological Barriers to Protein Delivery. Audus KL, Raub TJ (Eds.), Plenum Press, NY, USA (1993):161-178.
6. LEE VHL, ROBINSON JR: Topical ocular drug deHvery: recent developments and future challenges. J. Ocul. Pbarmacol. (1980) 2:67-108.
7. BANGA AK, CHIEN YW: Dermal absorption of peptides and proteins. In: Biological Barriers to Protein Delivery. Audus KL, Raub TJ (Ed.), Plenum Press, NY, USA (1993):179-197
8. BURTON PS, CONRADI RA, HILGERS RA: Mechanism of peptide and protein absorption. 2. Transcellular mechanism of peptide and protein absorption: Passive aspects. Adv. Drug Deliv. Res. (1991) 7:365-386.
9. SMITH PL, EDDY EP, LEE CP, AND WILSON G: Exploitation of the intestinal oligopeptide transporter to enhance drug absorption. Drug Deliv. (1993) 1:103-111.
10. HUNTER J, JEPSON MA, TSURUO T, SIMMONS ML, HIRST BH: Functional expression of a P-grycoproteln in apical membranes of human intestinal Caco-2 cells: Kinetics of vinblastine secretion and interaction with modulators.J. Btol. Chem. (1993) 268:14991-14997.
11. AUDUS KL, CHIKHALE P, MILLER D, THOMPSON SE, BORCHARDT RT: Brain uptake: Influence of chemical and biological factors. In: Advances In Drug Research. Testa B (Ed.), Academic Press. London UK (1992):l-64.
12. BROADWELL R D: Transcytosis of macromolecules through the blood-brain fluid barrier In vivo. In: Biological Barriers to Protein Delivery. Audus KL, Raub TJ (Eds), Plenum Press, NY, USA (1993):269-296.
13. MAUK AB, BIRMBOIM AS: Vascular endothelial barrier and its regulation. In Biological Barriers to Protein Delivery. Audus KL, Raub TJ (Eds) Plenum Press, NY, USA (1993):231-267.
14. Directed drug delivery: a multidisciplinary approach. Borchardt RT, Repta AJ, Stella VJ (Eds), Humana Press, NJ, USA (1985).
15. Advances in Drtig Delivery Systems. Anderson JM, Kim SW (Eds.), Eisevier Amsterdam (1986).
16. TAYLOR M, AMIDON G: In Peptide-Based Drug Design: Controlling Transport and Metabolism. Washington DC.: American Chemical Society (1995).
17. STELLA VJ, CHARMAN WNA, NARINGREKAR VH: Prodrugs: do they have advantages in clinical practice? Drugs (1995) 29:455-473.
18. YANG CY, DANTZIG All, PIDGEON: Intestinal peptide transport systems and oral drug availability. Pbarm. Res. (1999) 16:1331-1343.
19. TSUJI A, TAMAI I: Carrier-mediated intestinal transport of drugs. Pharm. Res. (1995) 13:963-977.
20. LIANG R, FEI YJ, PRASAD PD, RAMAMOORTHY S, HAN H, YANG-FENG L: Human intestinal HVpeptlde cotransporter; cloning, functional expression and chromosomal localization.J. Blol. Cbem. (1995) 270:6456-6463.
21. GANAPATHY V, DRANDSCH M, LEIBACH FH: Intestinal transport of amino acids and peptides. In: Physiology of the Gastrointestinal Tract. LR. Johnson (Ed.), Raven Press, NY, USA (1994):1773-1794.
22. HU M, SUBRAMANIAN P, MOSBERG HI, AMIDON GL Use of the peptide carrier system to improve the Intestinal absorption of L-alpha-methyldopa: carrier kinetics, intestinal permeabilities and in vitro hydrolysis of dipeptidyl derivatives of L-alpha-methyldopa. Pharm. Res. (1989) 6:66-70.
23. HUM, BORCHARDT RT: Mechanism of L-a-methyldopa transport through a monolayer of polarized human intestinal epithelial cells (Caco-2). Pbarm. Res. (1990) 7:1313-1319.
24. TSUJI A, TAMAI I, NAKANISHI M, AND AMIDON GL: Mechanism of absorption of the dipeptide cc-methyldopa-phe in the intestinal brush-border membrane vesicles. Pbarm. Res. (1990) 7:308-309.
25. BAI JP, HU M, SUBRAMANIAN P, MOSBERG HI, AND AMIDON GL: Utilization of peptide carrier system to improve intestinal absorption: targeting prolidase as a prodrug-convertlng enzyme. J. Pbarm. Sci. (1992) 81:113-116.
26. GRAPPEL SF, GIOVENELLA AJ, NISBET LJ: Activity of a peptidyl prodrug, alafosfalin, against anaerobic bacteria. Anttmtcrob. Agents Cbemother. (1985) 27:961-963.
27. SWAAN PW, TUKKER JJ: Carrier-mediated transport mechanism of foscarnet (trisodium phosphonoformate hexahydrate) in rat intestinal tissue.J. Phannacol. Exp. Tber. (1995) 272:242-247.
28. O'BRIEN J, CAMPOLI-RICHARDS DM: Acyclovh-. An updated review of its antiviral activity, Phamiacokinetic properties and therapeutic efficacy. Drugs (1989) 37:233-309.
29. BEAUCHAMP LM, ORR GF, DE MIRANDA P, BURNETTE T, KRENITSKY TA: Amino acid ester p rod rugs of acyclovir. Antiviral Cbetn. Cbemother. (1992) 3:157-164.
30. DE VRUEH RL, SMITH PL, LEE CP: Transport of L-valineacyclovir via the oligopeptide transporter in the human intestinal cell Une, Caco-2. J. Pbannacol. Exp. mer. (1998) 286:1166-1170.
31. HAN HK, DEVRUEH RLA, RHIE JK et al.: 5'-Amino acid ester of antiviral nucleosides, acyclovir and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pbatm. Res. 1998 15:1154-1159.
32. SINKO PJ, BAUMANE PV: Carrier-mediated intestinal absorption of valacyclovir, the L-vatyl ester prodrug of acyclovir: 1. Interactions with peptides, organic onions and organic cations in rats. Biopharm. Drug Dispos. (1998) 19:209-217.
33. GANAPATHY ME, HUANG W, WANG H, GANAPATHY V: Valacyclovir. a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Blochem. Biophys. Res. Commun. (1998) 246:470-475.
34. SUGAWARA M, HUANG W, FEI YJ, LEIBACH FH, GANAPATHY V, AND GANAPATHY ME: Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT 1 and PETT2. J. Pbarm. Sci. (2000) 89:781-789.
35. STEWART BH, KUGLER AR, THOMPSON PR, BOCKBRADER N: A saturable transport mechanism in the intestinal absorption of gabapentln is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Phann. Res. (1993) 10:276-281.
36. HEDIGER MA, KANAI Y, YOU G, NUSSBERGER S: Mammalian ion-coupled sohlte transporters. J Pbysiol. (1995) 482:7S-17S.
37. HEDIGER MA, COADY MJ, IKEDA TS, WRIGHT EM: Expression cloning and cDNA sequencing of the NaVgmcose cotransporter. Nature (1987) 330:379-381.
38. MIYAMOTO K, TATSUMI S, MORIMOTO A et al.: Characterization of the rabbit intestinal fructose transporter (GLUTS). Blocbem.J. (1994) 303:877-883
39. KAYANO T, BURANT CF, FUKUMOTO H et al.: Human facultative glucose transporters. J. Blol. Chcm. (1990) 265:13276-13282.
40. HAGA M, SAITO K, SHIMAYA T, MAEZAWA Y, KATO Y, KIM SW: Hypoglycémie effect of intestinally administered monosaccharide-modifted insulin derivatives in rats. Chcm. Pbarm. Bull. (1990) 38:1983-1986.
41. MIZUMA T, OHTA K, HAYASHI M, AWAZU S: Intestinal active absorption of sugar-conjugated compounds by glucose transport system: implication of improvement of poorly absorbable drugs. Biocbem. Pbarmacol. (1992) 43:2037-2039
42. MIZUMA T, OHTA K, HAYASHI M, AWAZU S: Comparative study of active absorption by the intestine and disposition of anomers of sugar-conjugated compounds. Biocbem. Pbarmacol. (1993) 45:1520-1523.
43. MIZUMA T, OHTA K, AWAZU S: The β-anomeric and glucose preferences of glucose transport carrier for intestinal active absorption of monosaccharide : conjugates. Biocbim. Btophys. Acta (1994) 1200:117-122.
44. +-Dependent transport of amlnopeptidease-resistant sugar-coupled tripeptides in rat intestine. Blocbcm. Blophys. Res. Commun. (1994) 203:1412-1416.
45. PRICE NT, JACKSON VN, HALESTRAP AP: Cloning and sequencing of four new mammalian moiiocarboxy late transporter (MCT) homologues confirms the existence of a transporter family with an ancient past. Biochem. J. (1998) 329:321-328.
46. YABUUCH1 H, TAMAI I, SAI Y, TSUJI A: Possible role of anion exchanger AE2 as the intestinal monocarboxylic acld/antiorter. Pharm. Res. (1998) 15:411-416.
47. TSUJI A, TAMAI I, NAKANISH1M, TERASAKIT, HAMANO S: Intestinal brush-border transport of the oral cephalosporin antibiotic, cefdinir, mediated by dipeptide and monocarboxylic acid transport systems in rabbits. J. Pharm. Pbannacol. (1993) 45:996-998.
48. ITOH T, TANNO M, U YH, YAMADA H: Transport of phenethicillin into rat intestinal brush border membrane vesicles: role of the monocarboxylic acid transport system. Int.J. Pbann. (1998) 172:103-112.
49. LI YH, TANNO M, ITOH T, YAMADA H: Role of the monocarboxylic acid transport system in the intestinal absorption of an orally active β-Iactam prodrug: carindacillin as a model. Int.J. Pbann. (1999) 191:151-159.
50. WILSON FA: Intestinal transport of bUe acids. Am. J. Physiol. (1981) 24l:G83-G92.
51. LACK L, WEINER IM: Intestinal bUe salt transport: structure-activity relationships and other properties. Am.J. Pbystol. (1966) 210:1142-1152.
52. KRAMER W, WESS G: BUe acid transport systems as pharmaceutical targets. Etirvp. J. Clin. Invest. (1996) 26:715-732.
53. HILL BT, RICHES PG: The absorption, distribution and excretion of 3H-chlorambuciI hi rats bearing the Yoshidaascites sarcoma. Br.J.Cancer(1971) 25:831-837.
54. KRAMER W, WESS G, SCHUBERT G et al.: Liver-specific drug targeting by coupling to bile acids. J. Biol. Chem. (1992) 267:18598-18604.
55. KRAMER W, WESS G, ENHSEN A et al: Bile acid derived HMG-CoA reductase inhibitors. Btocbtm. Biophys. Acta (1994) 1227:137-154.
56. WESS G, KRAMER W, BARTMANN W et al.: Modified bile acids: preparation of 7α,12α-dyhydroxy-3β- and 7α,12α-dihydrooxy-3α-(2-hydroxyethoxy)-5β-cholani c acid and their biological activity. Tetrahedron Lett. (1992) 33:195-198.
57. WESS G, KRAMER W, ENHSEN A, GLOMBIK H, BARINGHAUS KH, BOCK K, KLEINE H, SCILMITT W: Preparation of 3α and 3α-(w-aminoalkoxy)-7α, 12α-dihydroxy-5β-cholanoic acid esters: versatile shuttles for drug targeting. Tetrahedron Lett. (1993) 34:817-818.
58. WESS G, KRAMER W, SCHUBERT G etal.: Synthesis of bile acid-drug conjugates: potential drug-shuttles for liver specific targeting. Tetrahedron Lett. (1993) 34:819-822.
59. WANG J, SHEN D, SHEN WC: Oral delivery of an insulintransferrin conjugate in Streptozotocin-treated cf/1 mice. Pbarm. Res. (1997) 14:5469.
60. BALDWIN SA, MACKEY JR, CASS CE, YOUNG JD: Nucleoside transporters: molecular biology and implications for therapeutic development. Mol. Med. Today (1999) 5:216-224.
61. +-dependent nucleoside transporters. Pbarm. Res. (1997) 14:1524-1532.
62. DRESSER MJ, GRAY AT, GIACOMINI KM: Kinetic and selectivity differences between rodent, rabbit and human organic cation transporters (OCT1). J. Pharmacol. Exp. Ther. (2000) 292:1146-1152.
63. ZHANG L, BRETT CM, GIACOMINI KM: Role of organic cation transporters in drug absorption and elimination. Ann. Rev. Pharmacol. Toxicol. (1998) 38:431-460.
64. FEILD JA, ZHANG L, BRUN KA, BROOKS DP, EDWARDS RM: Cloning and functional characterization of a sodium-dependent phosphate transporter expressed in human hing and small intestine. Biochem. Biophys. Res. Comm. (1999) 258:578-582.
65. + and pH dependent transport of foscarnet via the phosphate carrier system across intestinal brush-border membrane. Biochem. Pharmacol. (1989) 38:1019-1022.
66. ISHIZAWA T, SADAHIRO S, HOSOI K, TAMAI I, TERASAKI T, TSUJI A: Mechanisms of intestinal absorption of the antibiotic, fosfomycin, in brush-border membrane vesicles in rabbits and humans. J. Pharmacobio. Dyn. (1992) 15:481-489.
67. ANDERSON RG, KAMEN BA, ROTHBERG KG, LACEY SW: Potocytosis: sequestration and transport of small molecules by caveolae. Science (1992) 255:410-411.
68. ROSS JF, CHAUDHURI PK, RATNAM M: Differential regulation of folate receptor isoforms in normal and malignant tissues In vivo and in established cell lines. Physiologic and clinical implications. Cancer (1994) 73:2432-2443.
69. FAN J, KURESHY N, VTTOLS KS, HUENNEKENS FM: Novel substrate analogs delineate an endocytotic mechanism for uptake of folate via the high-affinity, glycosylphosphatidylinositol-linked transport protein in L1210 mouse leukemia cells. Oncol. Res. (1995)7:511-516.
70. LEAMON CP, LOW PS: Membrane folate-binding proteins are responsible for folate-protein conjugate endocytosis into cultured cells. Biocbem. J. (1993) 291:855-860.
71. WANG S, LEE RJ, CAUCHON G, GORENSTEIN DG, LOW PS: Delivery of antisense oligodeoxyribounucleotides against the human epidermal growth factor receptor Into cultured KB cells with liposomes conjugated to folatc via polyethylene gh/coL Proc. Natl. Acad. Sci. USA (1995) 92:3318-3322.
72. RUSSELL-JONES GJ: Oral delivery of therapeutic proteins and peptides by the vitamin B12 uptake system. In: Peptlde-Bascd Drug Design: Controlling Transport and Metabolism. Taylor MD, Amidon GL (Eds.) :181-198. Washington DC: American Chemical Society (1995).
73. RUSSELL-JONES GJ, WESTWOOD SW, HABBERFIELD AD: Vitamin B12 mediated oral delivery systems for granulocyte-colony stimulating factor and erythropoietin. Bloconjug. Chcm. (1995) 6:459-465.
74. HABBERFIELD AD, JENSEN-PIPPO K, RALPH L, WESTWOOD SW, RUSSELL-JONES GJ: Vitamin B12-mediated uptake of recombinant therapeutic proteins from the gut. Int.J. Pbann. (1996) 145:1-8.
75. RUSSELL-JONES GJ, ARTHUR L, KILLINGER S, WESTWOOD SW: Vitamin B12-mediated transport of nanoparticles. Proc.Intl. Symp. Control Ret. Btoact.Mater. (1997) 24:11-12.
76. RUSSELL-JONES GJ, WESTWOOD SW, HABBERFIELD AD: The use of the vitamin Bi2 transport system as a carrier for the oral delivery of peptides, proteins and nanoparticles. Proc. Int. Symp. Control Rel. Bloact. Mater. (1996) 23:49-50.
77. WANGENSTEEN OD, BARTLETT ALM, JAMES JK, YANG ZF, LOW PS: Riboflavin-enhanced transport of serum albumin across the distal pulmonary epithelium. Pbann. Res. (1996) 13:1861-1864.
78. SWAAN PW: Recent advances in intestinal macromolecular drug delivery via receptor-mediated transport pathways. Pbann. Res. (1998) 15:826-834.
79. JEFFREY GP, BASCLAIN KA, ALLEN TL: Molecular regulation of transferrin receptor and ferritin expression in the rat gastrointestinal tract. Gastroenterology (1996) 110:790-800.
80. SHAH D, SHEN WC: Transcellular delivery of an insulintransferrin conjugate hi enterocyte-like Caco-2 cells. J Pharm. Sci. (1996) 85:1306-1311.
81. WANG J, SHEN D, SHEN WC: Oral delivery of an insulintransferrin conjugate in Streptozotocin-treated cf/1 mice. Pbann. Res. (1997) 14:8469.
82. HOKARI M, WU HQ, SCHWARCZ R, SMITH: Facilitated brain uptake of 4-chlorokynurenine and conversion to 7-chlorokynurenic acid. Keumreport QR (1996) 8:15-18.
83. BONINA FP, ARENARE L, PALAGIANO F et ah Synthesis, stability and pharmacological evaluation of nipecotic acid prodrugs. J Pbann. Sci. (1999) 88:561-567.
84. WALKER I, NICHOLLS D, IRWIN WJ, FREEMAN S: Drug delivery via active transport at the blood-brain barrier: affinity of a prodrug of phosphonoformate for the large amino acid transporter. J. Pbann. Sci. (1994) 84:157-167.
85. POLT R, PORRECA F, SZABO LZ et al.: Gtycopeptide enkephalln analogues produce analgesia in mice: evidence for penetration of the blood-brain barrier. Proc. Natl. Acad. Sci. USA (1994) 91:7114-7118.
86. BATTAGLIA G, RUSSA ML, BRUNO V et al; Systemically administered D-glucose conjugates of 7-chlorokynurenic acid are centrally available and exert anticonvulsant activity in rodents. Brain Res. (2000) 860:149-156.
87. JEFFERIES WA, BRANDON MR, WILLIAMS AF, HUNT SV: Analysis of lymphopoietic stem cells with a monoclonal antibody to the rat transferrin receptor. Immunology W85) 54:333-341.
88. PRIGENT SA, STANLEY KK, SIDDLE K: Identification of epitopes on the human Insulin receptor reacting -with rabbit polyclonal antisera and mouse monoclonal antibodies. J Blol. Chem. (1990) 265:9970-9977.
89. PARDRIDGE WM: Blood-brain barrier peptide transport and peptide drug delivery to the brain. In: Peptide-Based Drug Design: Controlling Transport and Metabolism. Taylor MD, Amidon GL (Eds). American Chemical Society. Washington DC (1995):265-296.
90. FRIDEN PM, WALUS LR, MUSSO GF, TAYLOR MA, MALFROY B, STARZYK RM: Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc. Natl. Acad. Set. (1991) 88:4771-4775.
91. WU D, PARDRIGE WM: CNS pharmacologie effect in conscious rats after intravenous injection of a biotinylatcd vasoactive intestinal peptide analogue coupled to a blood-brain barrier drug delivery system. J. Pharmacol. Exp. Tber. (1996) 279:77-83.
92. 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer's disease amyloid of the A beta 1-40/vector complex. Proc. Natl. Acad. Set. USA (1995) 92:10227-10231.
93. WU D, YANG J, PARDRIGE W M: Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. J. Clin. Int-cst. (1997) 100:1804-1812.
94. PARDRIGE WM, WU D, SAKANE T: Combined use of carboxyl-directed protein peglyation and vectormediated blood brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration, Pharm. Res. (1998) 15:576-582.
95. SAKANE T, PARDRIGE WM: Carboxyl-directed pegylalion of brain-derived neurotrophic factor markedly reduces systemic clearance with minimal loss of biological activity. Pharm. Res. (1997) 14:1085-1091.
96. BORCHARDT RT: Rational design of peptides with enhanced membrane permeability. In Medicinal Chemistry: Today, Tomorrow1. Yamazaki M (Ed) Blackwell, Oxford, UK (1995):191-196.
97. YANG C, MITRA AK: Nasal absorption of tyrosine linked model compounds. J Pharm. Set. (In Press).
98. YANG C, MITRA AK: Chemical stability, enzymatic hydrolysis and nasal uptake of amino acid ester prodnigs of acyclovlr. J. Pharm. Set. (In Press).